Drugs / 131I-L19SIP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01242943 | Nov 2008 → Feb 2011 | — | Philogen S.p.A. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131I-L19SIP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01242943 ↗ |
| Modality | Monoclonal antibody | “131I-L19SIP MONOCLONAL ANTIBODY” NCT01242943 ↗ |
| Route | Intravenous | “administration (intravenously)” NCT01242943 ↗ |